Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days after the companies disclosed that all regulatory conditions to close the deal were fulfilled.

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European Commission (EC) gave its approval in early December 2024. Catalent's common stock will no longer be listed on the New York Stock Exchange.

The all-cash deal has involved Novo Holdings acquiring Catalent for $16.5bn, including debt. It will then sell three of Catalent's factories – in Anagni, Italy, Brussels and Bloomington, Indiana – to Novo Nordisk for $11.7bn, enabling the Danish drugmaker to increase production of its obesity and diabetes treatments.

Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/16.DQzHZcKY.js